Nichols & Pratt Advisers’s AbbVie ABBV Stock Holding History

Nichols & Pratt Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.31M	Sell	24,432 -200	-0.8%	-$44.4K	0.34%	40
2025 Q4	$5.63M	Buy	24,632 +133	+0.5%	+$30.3K	0.35%	40
2025 Q3	$5.67M	Sell	24,499 -265	-1%	-$54K	0.36%	39
2025 Q2	$4.6M	Sell	24,764 -600	-2%	-$112K	0.31%	43
2025 Q1	$5.31M	Sell	25,364 -835	-3%	-$162K	0.36%	37
2024 Q4	$4.66M	Sell	26,199 -401	-2%	-$73.7K	0.31%	40
2024 Q3	$5.25M	Sell	26,600 -635	-2%	-$119K	0.34%	37
2024 Q2	$4.67M	Sell	27,235 -705	-3%	-$117K	0.32%	39
2024 Q1	$5.09M	Sell	27,940 -62	-0.2%	-$10.7K	0.34%	39
2023 Q4	$4.34M	Buy	28,002 +30	+0.1%	+$4.37K	0.31%	44
2023 Q3	$4.17M	Buy	27,972 +397	+1%	+$58.3K	0.32%	43
2023 Q2	$3.72M	Buy	27,575 +225	+0.8%	+$33K	0.27%	46
2023 Q1	$4.36M	Sell	27,350 -740	-3%	-$113K	0.34%	44
2022 Q4	$4.54M	Buy	28,090 +670	+2%	+$103K	0.36%	44
2022 Q3	$3.68M	Buy	27,420 +825	+3%	+$118K	0.33%	45
2022 Q2	$4.07M	Buy	26,595 +75	+0.3%	+$11.5K	0.33%	47
2022 Q1	$4.3M	Buy	26,520 +175	+0.7%	+$25.4K	0.31%	48
2021 Q4	$3.57M	Buy	26,345 +1,050	+4%	+$124K	0.25%	50
2021 Q3	$2.76M	Buy	25,295 +2,005	+9%	+$229K	0.21%	51
2021 Q2	$2.62M	Buy	23,290 +1,425	+7%	+$160K	0.2%	51
2021 Q1	$2.37M	Buy	21,865 +10,075	+85%	+$1.08M	0.18%	53
2020 Q4	$1.26M	Buy	11,790 +5,740	+95%	+$552K	0.1%	60
2020 Q3	$530K	Buy	6,050 +700	+13%	+$65.9K	0.05%	75
2020 Q2	$526K	Hold	5,350	–	–	0.05%	75
2020 Q1	$407K	Buy	5,350 +1,100	+26%	+$93.7K	0.04%	78
2019 Q4	$376K	Sell	4,250 -2,150	-34%	-$178K	0.03%	83
2019 Q3	$484K	Buy	6,400 +100	+2%	+$6.86K	0.04%	83
2019 Q2	$458K	Buy	6,300 +200	+3%	+$15.7K	0.04%	86
2019 Q1	$492K	Sell	6,100 -11,180	-65%	-$915K	0.04%	83
2018 Q4	$1.59M	Sell	17,280 -2,200	-11%	-$193K	0.15%	54
2018 Q3	$1.84M	Sell	19,480 -600	-3%	-$56.9K	0.15%	55
2018 Q2	$1.86M	Sell	20,080 -250	-1%	-$24.4K	0.17%	50
2018 Q1	$1.92M	Sell	20,330 -450	-2%	-$49.4K	0.18%	51
2017 Q4	$2.01M	Sell	20,780 -200	-1%	-$18.8K	0.17%	52
2017 Q3	$1.86M	Sell	20,980 -500	-2%	-$38.1K	0.17%	53
2017 Q2	$1.56M	Sell	21,480 -680	-3%	-$45.7K	0.14%	54
2017 Q1	$1.44M	Buy	22,160 +650	+3%	+$40.9K	0.13%	55
2016 Q4	$1.35M	Sell	21,510 -2,230	-9%	-$136K	0.13%	56
2016 Q3	$1.5M	Sell	23,740 -590	-2%	-$38.2K	0.14%	54
2016 Q2	$1.51M	Sell	24,330 -1,175	-5%	-$71.6K	0.14%	58
2016 Q1	$1.46M	Sell	25,505 -225	-0.9%	-$12.5K	0.13%	62
2015 Q4	$1.52M	Sell	25,730 -80	-0.3%	-$4.61K	0.15%	61
2015 Q3	$1.4M	Sell	25,810 -1,975	-7%	-$129K	0.14%	61
2015 Q2	$1.87M	Sell	27,785 -12,375	-31%	-$808K	0.17%	58
2015 Q1	$2.35M	Sell	40,160 -13,195	-25%	-$797K	0.21%	54
2014 Q4	$3.49M	Sell	53,355 -73,834	-58%	-$4.65M	0.31%	51
2014 Q3	$7.35M	Sell	127,189 -309,022	-71%	-$17.2M	0.65%	39
2014 Q2	$24.6M	Sell	436,211 -66,613	-13%	-$3.49M	2.13%	14
2014 Q1	$25.9M	Buy	502,824 +55,000	+12%	+$2.78M	2.34%	14
2013 Q4	$23.6M	Sell	447,824 -5,525	-1%	-$272K	2.22%	14
2013 Q3	$20.3M	Sell	453,349 -29,509	-6%	-$1.31M	2.04%	15
2013 Q2	$20M	Buy	+482,858	New	+$21.1M	2.09%	14

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nichols & Pratt Advisers's ABBV Position: Q1 2026 in Review

Nichols & Pratt Advisers reduced its AbbVie (ABBV) stake by 0.81% in Q1 2026, selling an estimated $44.4K and leaving 24,432 shares worth $5.31M. The position accounts for 0.34% of the portfolio, ranked #40.

Nichols & Pratt Advisers first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.9M in Q1 2014. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Nichols & Pratt Advisers held 24,432 shares of AbbVie worth $5.31M as of Q1 2026.
Nichols & Pratt Advisers sold 200 AbbVie shares in Q1 2026, an estimated $44.4K.
AbbVie made up 0.34% of Nichols & Pratt Advisers's portfolio in Q1 2026, its #40 holding.
Nichols & Pratt Advisers first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Nichols & Pratt Advisers's AbbVie position peaked at $25.9M in Q1 2014.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Nichols & Pratt Advisers's 13F filing for Q1 2026, filed 29 Apr 2026.